Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation

Sorafenib is a first-line molecular-target drug for advanced hepatocellular carcinoma (HCC), but its clinical effects are still limited. In this study we identify Quiescin sulfhydryl oxidase 1 (QSOX1) acting as a cellular pro-oxidant, specifically in the context of sorafenib treatment of HCC. QSOX1...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Jialei, Zhou, Chenhao, Zhao, Yue, Zhang, Xiaofei, Chen, Wanyong, Zhou, Qiang, Hu, Bo, Gao, Dongmei, Raatz, Lisa, Wang, Zhefang, Nelson, Peter J., Jiang, Yuchao, Ren, Ning, Bruns, Christiane J., Zhou, Haijun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024711/
https://www.ncbi.nlm.nih.gov/pubmed/33770521
http://dx.doi.org/10.1016/j.redox.2021.101942

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024711/
https://www.ncbi.nlm.nih.gov/pubmed/33770521
http://dx.doi.org/10.1016/j.redox.2021.101942

Ejemplares similares